Innovative Microbiome-based IBD Therapeutics to Be Developed Under New Partnership

Innovative Microbiome-based IBD Therapeutics to Be Developed Under New Partnership
Takeda Pharmaceutical, a Japanese biopharmaceutical company, announced a strategic new collaboration with NuBiyota to develop Microbial Ecosystem Therapeutics, a new form of treatment for patients with gastroenterology disorders who fail to respond to available treatments. The partnership will foster the development of oral microbial products using NuBiyota’s gut microbiome platform. The human gut microbiome consists of the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *